Asset
VK-2019
Cullinan Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03682055 | phase1_2 | terminated | 2019-04-04 | 2020-06-23 | Cullinan Therapeutics Inc. | Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) |
FDA applications (0)
This company has no applications containing this asset.